"As one of the top global producers of radioisotopes, NTP is pleased to enter into this mutual alliance with Lantheus Medical Imaging to ensure continued supply of Mo-99 for use in important diagnostic tests," said Don Robertson, managing director of NTP Radioisotopes (Pty) Ltd. "For more than 17 years, NTP has played a significant role in its contribution towards the diagnosis and treatment of illnesses. We hold a world-class record for reliability in terms of delivery and quantity of radioisotopes, and strive to work with our partners to minimize any risks to the routine supply of Mo-99."

About Molybdenum-99 and Technetium-99m
Over 22.5 million doses of diagnostic radiopharmaceuticals were injected into patients in the United States during 2008. Of these, nearly two-thirds were for cardiac exams, with the remaining for oncology, neurology and other applications. Technetium-99m (Tc99m), which is the decay product of molybdenum-99 (Mo-99), is the most commonly used medical radioisotope in the United States. At over 18.5 million doses, Tc99m accounted for 82% of all diagnostic radiopharmaceutical injections.2 Tc99m is used in Lantheus Medical Imaging's TechneLite® (Technetium Tc99m Generator) generators, which are distributed to hospitals and radiopharmacies as a source of Tc99m for diagnostic imaging procedures. Tc99m is also used with Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), one of the world's most widely-used cardiac imaging agents and the only technetium labeled myocardial perfusion agent that has been used to image more than 40 million patients. In diagnostic use, the Tc99m is attached to a specific molecule and injected into the patient. The diagnostic medicine then travels to the site or organ of interest and a special camera is used to pick up the gamma rays emitted from the radioactive material in the body and create images for diagnostic evaluation

About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for the past 50 years, is committed to advancing and investing in the field of diagnostic imaging. The company's proven success in discovering, developing and marketing innovative medical imaging agents provides a solid platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. The company is home to leading cardiac imaging brands, including Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, and TechneLite® (Technetium Tc99m Generator) and has nearly 700 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada, and Australia. For more information, visit www.lantheus.com.

More Voices